Title Fusion sequencing via terminator‐assisted synthesis ( FTAS ‐seq) identifies TMPRSS2 fusion partners in prostate cancer
Authors Drazdauskienė, Ugnė ; Kapustina, Žana ; Medžiūnė, Justina ; Dubovskaja, Varvara ; Sabaliauskaitė, Rasa ; Jarmalaitė, Sonata ; Lubys, Arvydas
DOI 10.1002/1878-0261.13428
Full Text Download
Is Part of Molecular oncology.. Hoboken : Wiley. 2023, vol. 17, iss. 6, p. 993-1006.. ISSN 1574-7891. eISSN 1878-0261
Keywords [eng] fusion transcripts ; prostate cancer ; RNA sequencing ; TMPRSS2 ; transcriptomics
Abstract [eng] Genetic rearrangements that fuse an androgen-regulated promoter area with a protein-coding portion of an originally androgen-unaffected gene are frequent in prostate cancer, with the fusion between transmembrane serine protease 2 (TMPRSS2) and ETS transcription factor ERG (ERG) (TMPRSS2-ERG fusion) being the most prevalent. Conventional hybridization- or amplification-based methods can test for the presence of expected gene fusions, but the exploratory analysis of currently unknown fusion partners is often cost-prohibitive. Here, we developed an innovative next-generation sequencing (NGS)-based approach for gene fusion analysis termed fusion sequencing via terminator-assisted synthesis (FTAS-seq). FTAS-seq can be used to enrich the gene of interest while simultaneously profiling the whole spectrum of its 30 -terminal fusion partners. Using this novel semi-targeted RNA-sequencing technique, we were able to identify 11 previously uncharacterized TMPRSS2 fusion partners and capture a range of TMPRSS2-ERG isoforms. We tested the performance of FTASseq with well-characterized prostate cancer cell lines and utilized the technique for the analysis of patient RNA samples. FTAS-seq chemistry combined with appropriate primer panels holds great potential as a tool for biomarker discovery that can support the development of personalized cancer therapies.
Published Hoboken : Wiley
Type Journal article
Language English
Publication date 2023
CC license CC license description